Daiichi Sankyo And Yakult File For Additional Approval Of Irinotecan For Childhood Malignant Solid Tumors
This article was originally published in PharmAsia News
Executive Summary
Daiichi Sankyo and Yakult announced Nov. 9 they have each filed for an additional indication of the cancer drug irinotecan (Daiichi’s Topotecin, Yakult’s Campto) for the treatment of pediatric malignant solid tumors.